Palmoplantar Keratoderma, Nonepidermolytic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Palmoplantar Keratoderma, Nonepidermolytic. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Palmoplantar Keratoderma, Nonepidermolytic receives a directional strategic score of 70/100, combining unmet need (86/100), competitive intensity (62/100, where higher means more competition) and market attractiveness (75/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

Abnormal thickening of the skin on the palms and soles charactersized by hyperkeratosis of the stratum corneum with no evidence of epidermolysis characteristic of epidermolytic hyperkeratosis. [PMID:7528239]

The reproducible entity is Patsnap disease ID 33711642657648c286d95353df86d09b with MeSH identifier C563422. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database

Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database ARTICLE OPEN Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database Camellia Edalat ]]]1, Matthew Spangler1, Jennifer Thorne2,3, Paulina Liberman ]]]2 and Meghan Berkenstock2✉ © The Author(s) 2025 BACKGROUND: Mucous membrane pemphigoid with ocular involvement (oMMP) is an autoimmune disease that results in chronic conjunctivitis, conjunctival scarring, and if left untreated, permanent vision loss. oMMP is quite rare with incidence rates between one in 12,000 to one in 60,000, but there is a lack of large population-based studies that focus solely on oMMP. Thus, we sought to examine the cumulative and annual incidence and prevalence of oMMP in the TriNetX database and compared these findings to the US population for greater generalizability.i METHODS: This was a retrospective study utilised International Classification of Disease, 10th edition (ICD-10) codes to determine the yearly and cumulative incidence and prevalence, demographics, ocular complications, and immunosuppressant treatments prescribed for oMMP from 2013 to 2023. TriNetX software was used to analyze the data. RESULTS: A total of 4052 patients were diagnosed with oMMP with a mean age of 73 years (SD =∠14; range 18–90). The majority of patients were female (n =∠2604 64.26%) and non-Hispanic, white (n =∠3098, 76.46%). Prednisone was the most common systemic medication prescribed to 40% of patients. The most

Review the epidemiology source

Epidemiology evidence 2: Incidence, prevalence, and mortality of localized scleroderma in Quebec, Canada: a population-based study Incidence,prevalence,andmortalityoflocalizedsclerodermainQuebec, Canada: a population-based study

1 Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64:217–228. 2 Pérez M, Zuccaro J, Mohanta A, et al. Feasibility of using elastog- raphy ultrasound in pediatric localized scleroderma (morphea). Ultrasound Med Biol. 2020;46:3218–3227. 3 Mahmood F, Nguyen A, Muntyanu A, et al. Prevalence and inci- dence of localized scleroderma: a qualitative systematic review. J Cutan Med Surg. 2022;26:632–633. 4 Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cu- mulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–173. 5 von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296. 6 Government of Canada, Canada S. Population and dwelling counts: Canada, provinces and territories. https://www150.statcan.gc.ca/t1/ tbl1/en/tv.action?pid=9810000101; 2022. Accessed January 25, 2024. 7 La RAMQ en quelques chiffres. https://www.ramq.gouv.qc.ca/en/ node/89526. Accessed May 17, 2023. 8 Bernatsky S, Dekis A, Hudson M, et al. Rheumatoid arthritis prevalence in Quebec. BMC Res Notes. 2014;7:937. 9 Shiff NJ, Lix LM, Joseph L, et al. The prevalence of systemic auto- immune rheumatic diseases in Canadian pediatric populations: administrative database estimates. Rheumatol Int. 2015;35:569–573. 10 Muntyanu A, Milan R, Kaouache M, et al. Tree-based machine learning to identify predictors of psoriasis incidence at the neigh- borho

Review the epidemiology source

Epidemiology evidence 3: Demographics, Trends, and Cardiovascular Mortality in Kaposi Sarcoma Patients in the United States: An Analysis of Surveillance, Epidemiology, and End Results Database Demographics, Trends, and Cardiovascular Mortality inKaposi Sarcoma Patients in the United States: AnAnalysis of Surveillance, Epidemiology, and End ResultsDatabase

1. O. Radu and L. Pantanowitz, “Kaposi Sarcoma,” Archives of Pathology & Laboratory Medicine 137, no. 2 (February 2013): 289–294, https://doi. org/10.5858/arpa.2012-0101-RS. 2. E. Cesarman, B. Damania, S. E. Krown, J. Martin, M. Bower, and D. Whitby, “Kaposi Sarcoma,” Nature Reviews Disease Primers 5, no. 1 (January 2019): 9, https://doi-org.sutd.idm.oclc.org/10.1038/s41572-019-0060-9. 3. R. Vangipuram and S. K. Tyring, “Epidemiology of Kaposi Sarcoma: Review and Description of the Nonepidemic Variant,” International Journal of Dermatology 58, no. 5 (May 2019): 538–542, https://doi-org.sutd.idm.oclc.org/ 10.1111/ijd.14080. 4. E. A. Mesri, E. Cesarman, and C. Boshoff, “Kaposi's Sarcoma and Its Associated Herpesvirus,” Nature Reviews Cancer 10, no. 10 (October 2010): 707–719, https://doi-org.sutd.idm.oclc.org/10.1038/nrc2888. 5. S. Peprah, E. A. Engels, M. J. Horner, et al., “Kaposi Sarcoma Incidence, Burden, and Prevalence in United States People With HIV, 2000‐2015,” Cancer Epidemiology, Biomarkers & Prevention 30, no. 9 (September 2021): 1627–1633, https://doi-org.sutd.idm.oclc.org/10.1158/1055-9965.EPI-21-0008. 6. N. Iftode, M. A. Rădulescu, Ș. S. Aramă, and V. Aramă, “Update on Kaposi Sarcoma‐Associated Herpesvirus (KSHV or HHV8) ‐ Review,” Romanian Journal of Internal Medicine 58, no. 4 (December 2020): 199– 208, https://doi-org.sutd.idm.oclc.org/10.2478/rjim-2020-0017. 7. D. L. White, A. Oluyomi, K. Royse, et al., “Incidence of AIDS‐Related Kaposi Sarcoma in All 50 United States From 2000 to 2014,” JAIDS Journal of Acquired Immune Deficiency Syndromes 81, no. 4 (August 2019): 387–394, https://doi-org.sutd.idm.oclc.org/10.1097/QAI.0000000000002050. 8. A. W. Armstrong, K. H. L

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Palmoplantar Keratoderma, Nonepidermolytic, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Palmoplantar Keratoderma, Nonepidermolytic thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: COL1A1

Type I collagen is a member of group I collagen (fibrillar forming collagen).

The mechanism anchor is COL1A1. It is a pathway hypothesis, not a claim that every Palmoplantar Keratoderma, Nonepidermolytic patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 36 registered studies. Recent sampled records include:

• ChiCTR2600125965 — Benvitimod Cream for the Treatment of Nagashima-type Palmoplantar Keratosis in Adults: A Prospective, Multicenter, Randomized, Double-Blind, Self-Controlled Study; Not yet recruiting; Not Applicable; sponsor Dongguan People's Hospital; enrollment 20.
• ChiCTR2600122580 — Research on the Development and Clinical Validation of Rapid Genetic Diagnostic Technology for Nagashima-type Palmoplantar Keratoderma; Pending; Not Applicable; sponsor Institute of Biomedical Engineering, Chinese Academy of Medical Sciences; enrollment 2000.
• CTRI/2026/04/107754 — Efficacy of local application of Madanadi Lepa in the treatment of Vipadika kushtha in children.; Not Yet Recruiting; Phase 2/3; sponsor Dr. Priyanka Chiripal; enrollment 60.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate COL1A1 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Palmoplantar Keratoderma, Nonepidermolytic merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if COL1A1 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Palmoplantar Keratoderma, Nonepidermolytic is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.